Myovant Sciences reports Q3 EPS (59c), consensus (47c)

Reports Q3 revenue $100.2M, consensus $102.36M. "During the third quarter fiscal year 2022, our brands had outstanding performance and double-digit growth over the prior quarter, with ORGOVYX expanding leadership in the GnRH antagonist class for advanced prostate cancer and MYFEMBREE reaching more patients with uterine fibroids and endometriosis while continuing to grow the GnRH antagonist class for these indications," said David Marek, Chief Executive Officer of Myovant Sciences, Inc. Mr. Marek added, "We are also excited that our special general meeting of shareholders to vote on the merger with Sumitovant Biopharma is scheduled for March 1, 2023. If approved, we anticipate the closing of the merger to occur shortly thereafter."